Literature DB >> 9791600

[Ebola virus: what the practitioner needs to know].

A J Georges1, S Baize, E M Leroy, M C Georges-Courbot.   

Abstract

The Ebola virus is an RNA virus of Filoviridae family. The earliest documented fatal epidemic of Ebola hemorrhagic occurred in 1976. There are four genetically different subtypes of Ebola virus. The virus remains in the blood for several weeks, can maintain its infectivity for several weeks at 20 degrees C outside the body, and survives for several weeks in corpses. Isolation of Ebola virus requires level 4 laboratory security conditions. Specimens are obtained by culturing mammal cells. Identification is achieved using reference serums. Serologic diagnosis is made using mainly ELISA technique for immunocapture of IgM or EBO Ag. The natural reservoir for Ebola virus is unknown. One possibility is that each isolated strain has a different reservoir. In recorded outbreaks, the index case has often had a history of contact with non-human primates. However since these animals are also highly sensitive to the virus, they cannot be considered as reservoirs but only as intermediate hosts. Transmission requires close contact such as occurs in association with health care, local customs, or funeral rites. In humans, infection causes hemorrhagic fever that progresses to diarrhea within 5 to 10 days. Recovery is observed in only 25% of cases. During outbreaks containment depends on implementation of simple precautions including isolation of suspected cases, appropriate protective clothing, disinfection with hypochlorite solutions, and proper waste disposal.

Entities:  

Mesh:

Year:  1998        PMID: 9791600

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  4 in total

1.  Ebola haemorrhagic fever among hospitalised children and adolescents in northern Uganda: epidemiologic and clinical observations.

Authors:  E Mupere; O F Kaducu; Z Yoti
Journal:  Afr Health Sci       Date:  2001-12       Impact factor: 0.927

2.  Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Authors:  Yu Cong; Julie Dyall; Brit J Hart; Lisa Evans DeWald; Joshua C Johnson; Elena Postnikova; Huanying Zhou; Robin Gross; Oscar Rojas; Isis Alexander; Nicole Josleyn; Tengfei Zhang; Julia Michelotti; Krisztina Janosko; Pamela J Glass; Mike Flint; Laura K McMullan; Christina F Spiropoulou; Tim Mierzwa; Rajarshi Guha; Paul Shinn; Sam Michael; Carleen Klumpp-Thomas; Crystal McKnight; Craig Thomas; Ann E Eakin; Kathleen G O'Loughlin; Carol E Green; Paul Catz; Jon C Mirsalis; Anna N Honko; Gene G Olinger; Richard S Bennett; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

3.  The physiology and pharmacology of singlet oxygen.

Authors:  Thomas W Stief
Journal:  Med Hypotheses       Date:  2003-04       Impact factor: 1.538

4.  What is Ebola?

Authors:  R A Stein
Journal:  Int J Clin Pract       Date:  2014-12-11       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.